HbA1c testing frequency and patient distributions by adherence level
| Low | Moderate | High | |
| (n=1928) | (n=2411) | (n=2085) | |
| HbA1c tests, median (IQR) | |||
| Performed during study period | 5 (4–7) | 8 (7–10) | 11 (11–13) |
| Age at baseline, mean (SD) | |||
| Age, year | 65.3 (11.9) | 66.7 (11.1) | 68.0 (10.6) |
| Gender, n (%) | |||
| Female | 920 (47.7) | 1103 (45.7) | 991 (47.5) |
| Male | 1008 (52.3) | 1308 (54.3) | 1094 (52.5) |
| SES at baseline, n (%) | |||
| 1 (most disadvantaged) | 295 (15.3) | 342 (14.2) | 267 (12.8) |
| 2 | 236 (12.2) | 265 (11.0) | 169 (8.1) |
| 3 | 423 (21.9) | 506 (21.0) | 509 (24.4) |
| 4 | 354 (18.4) | 499 (20.7) | 403 (19.3) |
| 5 (most advantaged) | 620 (32.2) | 799 (33.1) | 737 (35.3) |
| Remoteness at baseline, n (%) | |||
| Major cities | 1582 (82.1) | 1941 (80.5) | 1620 (77.7) |
| Regional/remote | 346 (17.9) | 470 (19.5) | 465 (22.3) |
| Medication at baseline, n (%) | |||
| Insulin | 246 (12.8) | 355 (14.7) | 289 (13.9) |
| Oral agents only | 1091 (56.6) | 1409 (58.4) | 1234 (59.2) |
| No medication | 591 (30.7) | 647 (26.8) | 562 (27.0) |
| Complications developed during study period, n (%) | |||
| Chronic kidney disease | 38 (2.0) | 89 (3.7) | 80 (3.8) |
| Ischaemic heart disease | 11 (0.6) | 21 (1.1) | 20 (1.0) |
HbA1c, glycated haemoglobin A1c; IQR, interquartile range ; SD, standard deviation; SES, socioeconomic status.